Fractyl Health, Inc. ( (GUTS)) has shared an update. On January 5, 2026, Fractyl Health outlined a catalyst-heavy 2026 plan centered on progressing Revita through pivotal validation in post-GLP-1 ...
Weight-loss injectables for pets? Okava Pharmaceuticals announced plans to kick off a pilot study of a GLP-1 drug for cats with obesity. (New York Times) Novo Nordisk submitted a higher-dose version ...
Diabetes mellitus is a multifactorial metabolic disorder characterized by chronic hyperglycemia and progressive multisystem complications. Growing evidences positions the microbiome (including ...
Fractyl Health specializes in disease-modifying therapies for obesity and T2D. Its aim is to address underlying causes of these conditions rather than just manage symptoms. The company's approach ...
Bariatric surgery, particularly RYGB and VSG, significantly improves liver health in MASLD, with high rates of steatosis remission and fibrosis reduction. Endoscopic techniques, such as ESG, IGBs, and ...
New U.S. patents strengthen Fractyl’s leadership in metabolic innovation by expanding its patent coverage of duodenal resurfacing, including thermal and non-thermal electrical energy applications ...
Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma arising from mucosal tissues, with distinct genomic and clinical characteristics compared with cutaneous melanoma (CM). Despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results